MedTech innovation designed for

cymactive™ is Ingenion Medical’s novel indwelling urinary catheter designed to mimic natural urination. It features a Malecot anchor and a magnetically controlled valve system called UroValve™, allowing users to void at their convenience—without needing a drainage bag or external tubing. It's approved for up to 30 days of continuous use.

Our current cymactive™ catheter is primarily for men experiencing chronic, non-neurogenic urinary retention. Future versions aim to support women, particularly those with severe incontinence and men with neurogenic urinary retention.

cymactive™ offers:

• Discreet, natural voiding without external urine collection bags or tubing.

• Enhanced autonomy—users control urination via a magnet.

• Supports risk reduction of Catheter-Associated Urinary Tract Infections (CAUTIs).

• Expected to contribute to a lower environmental impact versus single use intermittent catheters.

Yes, cymactive™ 2.0R received CE Mark approval in April 2024, enabling sales across the UK and EU.

Currently we have distributor partners in Greece, Cyprus, Benelux, Denmark, Slovakia, Italy and Turkey.

Absolutely. Ingenion Medical received a £277,000 SMART grant from Innovate UK in March 2022 to begin development of a female incontinence device (femactive™).

Use the Contact Us form at the bottom of this page or email the team at info@ingenionmedical.co.uk to inquire about availability and product demonstration. You may need validation depending on your location/market licencing.

The dynamic and dedicated team includes Edward Cappabianca (CEO), Zia Mursaleen (CFO), Susan Finch (COO), Tim Maloney (Commercial Director), and a strong Board of Directors featuring Chairman Dr. Sergio Rothstein and Non‑Executive Directors with deep experience in medical devices, healthcare, engineering, regulatory and marketing. We also are proud of having an highly supportive and knowledgeable Medical & Scientific Advisory Board.